Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.
Ruxolitinib, a groundbreaking product of Incyte Corp, has demonstrated an impressive evolution in the pharmaceutical market. Its strategic journey from a niche treatment for rare diseases to a versatile solution for more common dermatological conditions not only emphasizes the strategic significance Read More
Query Drug：AvacopanQuery Time：2024-05-10 16:41:47*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest doe Read More
Query Drug：RuxolitinibQuery Time：2024-04-25 09:12:38*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest Read More
IntroductionIn a previous article, we discussed when to consider using flow chemistry over conventional batch processes for chemical synthesis. One compelling example highlighting the advantages of flow chemistry comes from the manufacturing route development for belzutifan, a recently approved drug Read More
As one steps into the realm of pharmaceutical discovery, the name Eribulin, also known as Halaven, rings a powerful note. First approved in 2010 by Eisai, this non-peptide drug, intricate in its synthesis and impressive in the magnitude of its medical impact, has been nothing short of groundbreaking Read More
Why Choose Orally Dissolving Tablets (ODTs)?Orally dissolving tablets (ODTs) have revolutionized the pharmaceutical industry and patient care by enhancing drug life-cycle management and offering convenient dosing for patients who have difficulty swallowing, such as children, the elderly, and psychia Read More
Market potential of radiopharma & RDCsRDCs are currently being developed for cancer. According to the WHO IARC, in 2022, the five most common cancers resulted in 19,956,054 new cases and 9,736,520 deaths. It is estimated that by 2050, the incidence of all cancers will reach 35.3 million. Consequentl Read More
